CORRELATION BETWEEN APOB100/APOA1 RATIO AND INSULIN RESISTANCE IN TYPE 2 DIABETES MELLITUS: Apolipoproteins and Type 2 diabetes mellitus

SUCHETHA KUMARI N; SHILPA S SHETTY

doi:10.22159/ajpcr.2020.v13i2.36431

Authors

SUCHETHA KUMARI N Department of Biochemistry, K.S. Hegde Medical Academy, Mangalore, Karnataka, India.
SHILPA S SHETTY Central Research Laboratory, K.S. Hegde Medical Academy, Nitte (Deemed to be University), Mangalore, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2020.v13i2.36431

Keywords:

Apolipoproteins, Insulin resistance, Diabetes, Dyslipidemia

Abstract

Objective: Various lipid abnormalities are associated with Type 2 diabetes, thereby increasing the risk of cardiovascular disease and metabolic syndrome. The objective of the study is to correlate apolipoprotein ratio with insulin resistance (IR) to understand its role in Type 2 diabetes mellitus.

Methods: The study population included 416 subjects of which 197 were non-diabetic and remaining 219 were non-diabetic and served as control subjects. Body mass index was calculated. Fasting plasma glucose, insulin, glycated hemoglobin levels, total cholesterol, triglyceride and high-density lipoprotein, ApoA-1, and ApoB-100 were measured using commercially available kits. Statistical analysis was performed with SPSS for Windows 16.0. Significance was defined as p<0.05.

Results: Apolipoprotein A-1 levels were lower in the diabetic group whereas apolipoprotein B-100 levels, apolipoprotein ratios were higher in the diabetic group. ApoB100 and apolipoportein ratio showed a positive correlation with IR.

Conclusions: The study results indicate that apolipoprotein B100/ApoA-1 ratio can act as a strong biomarker for IR.

Downloads

Download data is not yet available.

References

Garg G, Agarwal PK, Manocha A, Garg A. Apolipoprotein levels in Type 2 diabetes mellitus patients. Curr Med Res Pract 2016;6:59.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.

Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.

Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J 2014;7:45-8.

DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: A meta-analysis of data from eleven prospective studies. Diabetologia 2004;47:1245-56.

Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki policemen study. Arterioscler Thromb Vasc Biol 2000;20:538-44.

Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.

Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375:181-3.

Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005;28:1769-78.

McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.

Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.

Alberti KG, Zimmet P, Shaw J. Metabolic syndrome a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006;23:469-80.

Walldius G. In: Kostner G, Editor. The ApoB/ApoA-I Ratio is a Strong Predictor of Cardiovascular Risk, Lipoproteins Role in Health and Diseases. London: In Tech; 2012.

Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988;29:1461-73.

Ying X, Qian Y, Jiang Y, Jiang Z, Song Z, Zhao C. Association of the apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein cholesterol with insulin resistance in a Chinese population with abdominal obesity. Acta Diabetol 2012;49:465-72.

Mohammadi Z, Fayyazbakhsh F, Ebrahimi M, Amoli MM, Khashayar P, Dini M, et al. The association between the apolipoprotein A1 high density lipoprotein-cholesterol and diabetes in Taiwan a cross-sectional study. BMC Endocr Disord 2013;13:42.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

Bodhe C, Jankar D, Bhutada T, Patwardhan M, Patwardhan V. HbA1c: Predictor of dyslipidemia and atherogenicity in diabetes mellitus. Int J Basic Med Sci Pharm 2012;2:25.

Shetty SS, Devi UH, Kumari SN. Relationship between glycated hemoglobin and serum lipid profile in Type 2 diabetes mellitus a case-control study. Br J Med Med Res 2016;16:1-6.

Misra A, Luthra K, Vikram NK. Dyslipidemia in Asian Indians: Determinants and significance. J Assoc Physicians India 2004;52:137-42.

Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 2007;22:359-67.

Barkas F, Elisaf M, Liberopoulos E, Liontos A, Rizos EC. High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. Atherosclerosis 2016;247:58-63.

Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, et al. Association of apolipoprotein B with incident Type 2 diabetes in an aboriginal Canadian population. Clin Chem 2010;56:666-70.

Walldius G, Jungner I. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy a review of the evidence. J Intern Med 2006;259:493-519.

Scharnagl H, März W. New lipid-lowering agents acting on LDL receptors. Curr Top Med Chem 2005;5:233-42.

Onat A, Hergenç G, Bulur S, Uğur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident Type-2 diabetes among Turks. Int J Cardiol 2010;142:72-9.

Hwang YC, Ahn HY, Kim WJ, Park CY, Park SW. Increased apoB/A-I ratio independently associated with Type 2 diabetes mellitus: Cross-sectional study in a Korean population. Diabet Med 2012;29:1165-70.

De BK, Mani S, Mandal SK, Mondal SS, Bhattacharya R, Pramanik AB. Cryptogenic cirrhosis: Metabolic liver disease due to insulin resistance. Indian J Med Sci 2010;64:508-19.